2342.T | Trans Genic Inc.

Market Cap (In JPY)

3.01 Billion

Revenue (In JPY)

13.08 Billion

Net Income (In JPY)

4.08 Million

Avg. Volume

48.24 Thousand

Company Profile

Sector: Healthcare
Industry: Biotechnology
CEO: Kenji Fukunaga
Employee Count: -
Website: https://www.transgenic.co.jp
Ipo Date: 2002-12-10
Details: Trans Genic Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of clinical trial reports; as well as hospital support services. It also offers drug efficiency and pharmacological test and safety studies; sugar chain analysis and synthesis services; advice and support services, including M&A, business revitalization, business succession services; and contract production services, such as genetically modified mice, antibodies, protein hypers, and expressing cells, as well as sells mouse-related products and mouse models, and research reagents. The company was formerly known as Kumamoto Immunochemical Laboratories Inc. and changed its name to Trans Genic Inc. in April 2000. Trans Genic Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.